ACCSAP CCKE Coronary Artery Disease (CAD): Risk Stratification and Prevention Practice Test 2026 - Free CAD Risk Stratification and Prevention Practice Questions and Study Guide

Understanding how risk differs for pharmacologic stress testing helps explain why a large abdominal aortic aneurysm is considered a relative contraindication. Some conditions make pharmacologic stress testing unsafe in almost all cases (absolute contraindications), while others raise concern but may be acceptable if the potential benefit outweighs the risk (relative contraindications). A large abdominal aortic aneurysm fits the latter category. The vasodilators used to induce coronary hyperemia cause systemic vasodilation and can lead to hypotension and rapid hemodynamic changes. In a patient with a sizeable aneurysm, these shifts could theoretically increase wall stress on the aneurysm or worsen the risk of rupture, so clinicians approach with caution or consider an alternative test.

In contrast, hypotension, recently treated acute coronary syndrome within 24 hours, and severe left ventricular failure are more clear-cut safety concerns for pharmacologic stress testing. They can worsen perfusion, provoke dangerous ischemia, or overwhelm the heart’s limited reserve, making the test unsafe or inappropriate in the acute setting.

If a patient has a large abdominal aortic aneurysm, an alternative approach—such as exercise-based testing if feasible, or imaging that does not rely on pharmacologic stress—may be chosen to minimize risk while still assessing for ischemia.